Back to top

Image: Bigstock

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Read MoreHide Full Article

Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure helps cut through all the noise.

The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.

Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.

The Zacks Earnings ESP, Explained

The Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.

With this in mind, the Expected Surprise Prediction compares the Most Accurate Estimate (being the most recent) against the overall Zacks Consensus Estimate. The percentage difference provides the ESP figure. The system also utilizes our core Zacks Rank to provide a stronger system for identifying stocks that might beat their next quarterly earnings estimate and possibly see the stock price climb.

In fact, when we combined a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. Perhaps most importantly, using these parameters has helped produce 28.3% annual returns on average, according to our 10 year backtest.

Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.

Should You Consider Merck?

The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Merck (MRK - Free Report) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $1.93 a share 30 days away from its upcoming earnings release on October 31, 2024.

Merck's Earnings ESP sits at +9.33%, which, as explained above, is calculated by taking the percentage difference between the $1.93 Most Accurate Estimate and the Zacks Consensus Estimate of $1.77. MRK is also part of a large group of stocks that boast a positive ESP. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

MRK is one of just a large database of Medical stocks with positive ESPs. Another solid-looking stock is TransMedics (TMDX - Free Report) .

Slated to report earnings on November 4, 2024, TransMedics holds a #2 (Buy) ranking on the Zacks Rank, and it's Most Accurate Estimate is $0.38 a share 34 days from its next quarterly update.

TransMedics' Earnings ESP figure currently stands at +39.88% after taking the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $0.27.

Because both stocks hold a positive Earnings ESP, MRK and TMDX could potentially post earnings beats in their next reports.

Find Stocks to Buy or Sell Before They're Reported

Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Merck & Co., Inc. (MRK) - free report >>

TransMedics Group, Inc. (TMDX) - free report >>

Published in